<DOC>
	<DOCNO>NCT01727206</DOCNO>
	<brief_summary>The study propose pilot phase II , interventional , treatment , open-label , single-arm , efficacy/safety clinical trial 6-month treatment tocilizumab ( 8 mg/kg monthly ) adult patient extraskeletal Erdheim-Chester disease ( ECD ) . Efficacy assessed effect treatment size measurable lesion , evaluate bidimensional measurement , impact treatment symptom control patient quality life . Safety treatment determine analysis adverse event relevant safety laboratory parameter . Secondary objective study : 1. good characterize mechanism underlie disease possible response treatment . In particular : ) investigate immunophenotypic histomorphologic feature ECD histiocytes ; ii ) gather gene expression data peripheral blood immune cell well characterize functional status , define transcriptional fingerprint possible modulation result tocilizumab treatment ; iii ) ass production soluble mediator expression activation molecule monocytes derived ECD patient , well stimulation select inflammatory cytokine ; iv ) investigate ex vivo vitro impact tocilizumab treatment marker , possible use predictor indicator response treatment . 2. investigate metabolic pattern ECD patient tocilizumab treatment evaluate fluoro-d-glucose positron emission tomography ( FDG-PET ) verify indicator ECD activity .</brief_summary>
	<brief_title>Pilot Study Tocilizumab Patients With Erdheim-Chester Disease</brief_title>
	<detailed_description />
	<mesh_term>Erdheim-Chester Disease</mesh_term>
	<criteria>patient &gt; = 18 year age able understand sign inform consent ; histologically prove diagnosis ErdheimChester disease ; advanced disease limit skeleton , least one measurable lesion ; female childbearing potential , negative pregnancy test willingness adhere highly effective contraceptive method birth control duration study ; history hypersensitivity tocilizumab excipients ; ï¿¼ severe infection require hospitalization antibiotic therapy 30 day enrollment study ; active tuberculosis , listeriosis , histoplasmosis , sepsis , abscess , opportunistic infection ; active hepatitis B C virus infection ; past history tuberculosis ( document positive purify protein derivative ( PPD ) skin test and/or positive Quantiferon test and/or chest X ray ) , absence document appropriate administration specific treatment latent tuberculosis ; history human immunodeficiency virus ( HIV ) infection ; past history ( &lt; 5 year enrollment ) lymphoproliferative disorder solid cancer ( exclude cure basal cell squamous cell carcinoma skin ) ; moderate severe heart failure ( NYHA class III/IV ) , uncontrolled diabetes mellitus disease accord physician charge protocol may harm patient , he/she would enroll study ; history alcohol and/or drug abuse ; prior treatment alkylating drug ( chlorambucil , cyclophosphamide ) ; serum creatinine &gt; 1.6 mg/dL female patient &gt; 1.9 mg/dL male patient , aspartate aminotransferase and/or alanine aminotransferase &gt; 3 x upper limit normal ; platelet &lt; 100.000/fL ; hemoglobin &lt; 8.5 g/dL ; white blood cell count &lt; 1000/fL ; lymphocyte &lt; 500/fL ; total bilirubin &gt; 2.0 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Erdheim-Chester disease</keyword>
	<keyword>Tocilizumab</keyword>
	<keyword>Treatment</keyword>
	<keyword>Phase II</keyword>
</DOC>